MX2020011636A - Derivados de quinolina como inhibidores del receptor de tirosina cinasa (axl/mer rtk) y del receptor del factor 1 estimulante de colonias (csf1r). - Google Patents
Derivados de quinolina como inhibidores del receptor de tirosina cinasa (axl/mer rtk) y del receptor del factor 1 estimulante de colonias (csf1r).Info
- Publication number
- MX2020011636A MX2020011636A MX2020011636A MX2020011636A MX2020011636A MX 2020011636 A MX2020011636 A MX 2020011636A MX 2020011636 A MX2020011636 A MX 2020011636A MX 2020011636 A MX2020011636 A MX 2020011636A MX 2020011636 A MX2020011636 A MX 2020011636A
- Authority
- MX
- Mexico
- Prior art keywords
- csf1r
- axl
- cancer
- inhibitors
- treatment
- Prior art date
Links
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 abstract 3
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 206010062016 Immunosuppression Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010070308 Refractory cancer Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 230000006028 immune-suppresssive effect Effects 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000015788 innate immune response Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 abstract 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 abstract 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862677902P | 2018-05-30 | 2018-05-30 | |
| PCT/EP2019/064214 WO2019229251A1 (en) | 2018-05-30 | 2019-05-31 | Quinoline derivatives as inhibitors of axl/mer rtk and csf1r |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020011636A true MX2020011636A (es) | 2020-12-07 |
Family
ID=66770463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011636A MX2020011636A (es) | 2018-05-30 | 2019-05-31 | Derivados de quinolina como inhibidores del receptor de tirosina cinasa (axl/mer rtk) y del receptor del factor 1 estimulante de colonias (csf1r). |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12162858B2 (enExample) |
| EP (1) | EP3774776A1 (enExample) |
| JP (2) | JP7390313B2 (enExample) |
| CN (1) | CN112313216B (enExample) |
| AU (1) | AU2019276359B2 (enExample) |
| BR (1) | BR112020021370A2 (enExample) |
| CA (1) | CA3097694A1 (enExample) |
| IL (1) | IL278960B2 (enExample) |
| MX (1) | MX2020011636A (enExample) |
| PH (1) | PH12020551806A1 (enExample) |
| SG (1) | SG11202009971QA (enExample) |
| WO (1) | WO2019229251A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| KR20240168318A (ko) * | 2022-03-30 | 2024-11-29 | 주식회사 큐리언트 | N-(5-((6,7-디메톡시퀴놀린-4-일)옥시)피리딘-2-일)-1-프로필-4-(2,2,2-트리플루오로에톡시)-1h-피라졸-3-카르복사미드염산염의 신규 형태 |
| CN117637185B (zh) * | 2024-01-25 | 2024-04-23 | 首都医科大学宣武医院 | 一种基于影像的颅咽管瘤治疗辅助决策方法、系统及设备 |
| CN118593494B (zh) * | 2024-08-08 | 2024-11-01 | 四川大学华西医院 | Nampt抑制剂在制备预防和/或治疗色素沉着绒毛结节性滑膜炎的药物中的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143764A (en) | 1995-11-07 | 2000-11-07 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same |
| EP2311809A1 (en) | 2009-10-16 | 2011-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinolinyloxyphenylsulfonamides |
| EP2423208A1 (en) * | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
| CA2820709C (en) | 2011-02-28 | 2016-02-16 | Sunshine Lake Pharma Co., Ltd. | Substituted quinoline compounds and methods of use |
| US10208034B2 (en) | 2014-12-25 | 2019-02-19 | Ono Pharmaceutical Co., Ltd. | Quinoline derivative |
| RU2750727C9 (ru) | 2015-04-14 | 2021-08-16 | Кьюриент Ко., Лтд. | Фармацевтически активные соединения в качестве ингибиторов рецепторной тирозинкиназы семейства там |
| CA3101983A1 (en) | 2018-06-01 | 2019-12-05 | Rigel Pharmaceuticals, Inc. | Quinoline derivatives useful as tyrosine kinase inhibitors |
-
2019
- 2019-05-31 CA CA3097694A patent/CA3097694A1/en active Pending
- 2019-05-31 SG SG11202009971QA patent/SG11202009971QA/en unknown
- 2019-05-31 MX MX2020011636A patent/MX2020011636A/es unknown
- 2019-05-31 WO PCT/EP2019/064214 patent/WO2019229251A1/en not_active Ceased
- 2019-05-31 IL IL278960A patent/IL278960B2/en unknown
- 2019-05-31 CN CN201980036560.3A patent/CN112313216B/zh active Active
- 2019-05-31 AU AU2019276359A patent/AU2019276359B2/en active Active
- 2019-05-31 JP JP2020565928A patent/JP7390313B2/ja active Active
- 2019-05-31 US US17/047,961 patent/US12162858B2/en active Active
- 2019-05-31 BR BR112020021370-5A patent/BR112020021370A2/pt unknown
- 2019-05-31 EP EP19728645.3A patent/EP3774776A1/en active Pending
-
2020
- 2020-10-29 PH PH12020551806A patent/PH12020551806A1/en unknown
-
2023
- 2023-10-06 JP JP2023174642A patent/JP2023168629A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019229251A1 (en) | 2019-12-05 |
| JP2023168629A (ja) | 2023-11-24 |
| KR20210020882A (ko) | 2021-02-24 |
| SG11202009971QA (en) | 2020-11-27 |
| CN112313216B (zh) | 2025-03-14 |
| IL278960A (en) | 2021-01-31 |
| NZ768747A (en) | 2025-06-27 |
| AU2019276359B2 (en) | 2024-10-03 |
| EP3774776A1 (en) | 2021-02-17 |
| CA3097694A1 (en) | 2019-12-05 |
| JP2021525270A (ja) | 2021-09-24 |
| US20210163448A1 (en) | 2021-06-03 |
| BR112020021370A2 (pt) | 2021-01-19 |
| US12162858B2 (en) | 2024-12-10 |
| IL278960B2 (en) | 2024-08-01 |
| PH12020551806A1 (en) | 2021-05-17 |
| AU2019276359A1 (en) | 2020-10-29 |
| JP7390313B2 (ja) | 2023-12-01 |
| IL278960B1 (en) | 2024-04-01 |
| CN112313216A (zh) | 2021-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551806A1 (en) | Quinoline derivatives as inhibitors of axl/mer rtk and csf1r | |
| PH12017501822A1 (en) | Quinoline derivatives as tam rtk inhibitors | |
| EA201890730A1 (ru) | Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования | |
| PH12020550881A1 (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| PH12022550039A1 (en) | Peptide conjugates of cytotoxins as therapeutics | |
| EA027213B9 (ru) | Соединения пиразолопиримидина в качестве ингибиторов киназ | |
| MX377305B (es) | DERIVADOS DE IMIDAZO[4,5-c]QUINOLINA E IMIDAZO[4,5-c][1,5]NAFTIRIDINA NOVEDOSOS COMO INHIBIDORES DE LRRK2. | |
| AU2016256469A8 (en) | Methods for treating cancer | |
| MX2020012165A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer. | |
| PH12015502414A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
| EA201792619A1 (ru) | Нафтиридиновые соединения в качестве ингибиторов jak киназы | |
| EA033284B1 (ru) | ПРОИЗВОДНЫЕ 8-[6-[3-(АМИНО)ПРОПОКСИ]-3-ПИРИДИЛ]-1-ИЗОПРОПИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ МОДУЛЯТОРОВ КИНАЗЫ МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ (ATM) ДЛЯ ЛЕЧЕНИЯ РАКА | |
| EA201692483A1 (ru) | Ингибиторы гистоновой метилазы | |
| EA201790502A1 (ru) | Ингибиторы гистоновых диметилаз | |
| MX2022003907A (es) | Compuestos y composiciones y usos de los mismos. | |
| EA202090497A1 (ru) | Соединения и композиции для лечения гематологических нарушений | |
| AU2015314007B2 (en) | Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers | |
| MX2020006614A (es) | Derivados de cromenopiridina como inhibidores de fosfatidilinositol fosfato cinasa,. | |
| EA201791369A1 (ru) | Твердые формы конденсированных гетероароматических пирролидинонов | |
| MX2017003466A (es) | Inhibidores de histona desmetilasa. | |
| PH12019501534A1 (en) | Csf1r-based chimeric proteins | |
| EA202090414A1 (ru) | Соединения и их применение | |
| PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
| MA38654B1 (fr) | Dérivés de type promédicament de triazolopyridines substituées | |
| PH12021552389A1 (en) | Quinoline derivatives and their use for the treatment of cancer |